REFILE-UPDATE 2-Pfizer boosts cancer drug pipeline with $14 bln Medivation deal

Aug 22 (Reuters) - Pfizer Inc said on Monday it

would buy U.S. cancer drug company Medivation Inc in a

deal valued at about $14 billion, adding blockbuster prostate

cancer drug Xtandi to its portfolio.

Read more